These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 16738009)

  • 41. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.
    Ousterout DG; Kabadi AM; Thakore PI; Perez-Pinera P; Brown MT; Majoros WH; Reddy TE; Gersbach CA
    Mol Ther; 2015 Mar; 23(3):523-32. PubMed ID: 25492562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemical treatment enhances skipping of a mutated exon in the dystrophin gene.
    Nishida A; Kataoka N; Takeshima Y; Yagi M; Awano H; Ota M; Itoh K; Hagiwara M; Matsuo M
    Nat Commun; 2011; 2():308. PubMed ID: 21556062
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exon skipping therapy for Duchenne muscular dystrophy.
    Kole R; Krieg AM
    Adv Drug Deliv Rev; 2015 Jun; 87():104-7. PubMed ID: 25980936
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene.
    Aretz S; Uhlhaas S; Sun Y; Pagenstecher C; Mangold E; Caspari R; Möslein G; Schulmann K; Propping P; Friedl W
    Hum Mutat; 2004 Nov; 24(5):370-80. PubMed ID: 15459959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family.
    Ginjaar IB; Kneppers AL; v d Meulen JD; Anderson LV; Bremmer-Bout M; van Deutekom JC; Weegenaar J; den Dunnen JT; Bakker E
    Eur J Hum Genet; 2000 Oct; 8(10):793-6. PubMed ID: 11039581
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping.
    Bertoni C; Lau C; Rando TA
    Hum Mol Genet; 2003 May; 12(10):1087-99. PubMed ID: 12719373
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Local dystrophin restoration with antisense oligonucleotide PRO051.
    van Deutekom JC; Janson AA; Ginjaar IB; Frankhuizen WS; Aartsma-Rus A; Bremmer-Bout M; den Dunnen JT; Koop K; van der Kooi AJ; Goemans NM; de Kimpe SJ; Ekhart PF; Venneker EH; Platenburg GJ; Verschuuren JJ; van Ommen GJ
    N Engl J Med; 2007 Dec; 357(26):2677-86. PubMed ID: 18160687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides.
    Aartsma-Rus A; Janson AA; Heemskerk JA; De Winter CL; Van Ommen GJ; Van Deutekom JC
    Ann N Y Acad Sci; 2006 Oct; 1082():74-6. PubMed ID: 17145928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interplay between exonic splicing enhancers, mRNA processing, and mRNA surveillance in the dystrophic Mdx mouse.
    Buvoli M; Buvoli A; Leinwand LA
    PLoS One; 2007 May; 2(5):e427. PubMed ID: 17487273
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of hprt splicing mutations induced by the ultimate carcinogenic metabolite of benzo[a]pyrene in Chinese hamster V-79 cells.
    Hennig EE; Conney AH; Wei SJ
    Cancer Res; 1995 Apr; 55(7):1550-8. PubMed ID: 7882364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Categorization of 77 dystrophin exons into 5 groups by a decision tree using indexes of splicing regulatory factors as decision markers.
    Malueka RG; Takaoka Y; Yagi M; Awano H; Lee T; Dwianingsih EK; Nishida A; Takeshima Y; Matsuo M
    BMC Genet; 2012 Mar; 13():23. PubMed ID: 22462762
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A nonsense mutation-created intraexonic splice site is active in the lymphocytes, but not in the skeletal muscle of a DMD patient.
    Tran VK; Takeshima Y; Zhang Z; Habara Y; Haginoya K; Nishiyama A; Yagi M; Matsuo M
    Hum Genet; 2007 Jan; 120(5):737-42. PubMed ID: 17024373
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Two alternative exons can result from activation of the cryptic splice acceptor site deep within intron 2 of the dystrophin gene in a patient with as yet asymptomatic dystrophinopathy.
    Yagi M; Takeshima Y; Wada H; Nakamura H; Matsuo M
    Hum Genet; 2003 Feb; 112(2):164-70. PubMed ID: 12522557
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel cryptic exon in intron 2 of the human dystrophin gene evolved from an intron by acquiring consensus sequences for splicing at different stages of anthropoid evolution.
    Dwi Pramono ZA; Takeshima Y; Surono A; Ishida T; Matsuo M
    Biochem Biophys Res Commun; 2000 Jan; 267(1):321-8. PubMed ID: 10623618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
    Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
    J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6.
    Raponi M; Kralovicova J; Copson E; Divina P; Eccles D; Johnson P; Baralle D; Vorechovsky I
    Hum Mutat; 2011 Apr; 32(4):436-44. PubMed ID: 21309043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients.
    Helderman-van den Enden AT; Straathof CS; Aartsma-Rus A; den Dunnen JT; Verbist BM; Bakker E; Verschuuren JJ; Ginjaar HB
    Neuromuscul Disord; 2010 Apr; 20(4):251-4. PubMed ID: 20153965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Two silent substitutions in the PDHA1 gene cause exon 5 skipping by disruption of a putative exonic splicing enhancer.
    Boichard A; Venet L; Naas T; Boutron A; Chevret L; de Baulny HO; De Lonlay P; Legrand A; Nordman P; Brivet M
    Mol Genet Metab; 2008 Mar; 93(3):323-30. PubMed ID: 18023225
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.